Generic drugs coming on the market in the next two years could save upstate New Yorkers more than $447 million a year, according to a new report from Rochester–based Excellus BlueCross BlueShield.
The savings would come from 14 brand-name prescription drugs that will be newly available as generics in 2013 and another 23 in 2014, according to the report from Excellus, one of Central New York’s major health insurers. The drugs include Cymbalta, Diovan, Nexium, and Niaspan, which treat conditions including depression, fibromyalgia, high blood pressure, heartburn, and high cholesterol.
“As expensive brand-name drugs become available as generics, the savings to consumers can be significant, both in terms of lower retail prices for those who pay out-of-pocket and lower co-pays for those with insurance coverage,” Mona Chitre, Excellus vice president of pharmacy management, said in a news release. “Importantly, consumers should understand that generics are approved by the Food and Drug Administration as being as safe and effective as their brand-name counterparts, so they can be confident in the generics’ efficacy.”
(Sponsored)
It’s Time for Your Business to Think About Year-End Tax Planning
As the year-end approaches, it’s time to take proactive steps to help lower your business’s taxes for 2024 and beyond. Deferring income and accelerating deductions to minimize taxes can be
The Influence of Economic Uncertainty on Business Value
Businesses face uncertain conditions today, including geopolitical and cybersecurity risks, inflation concerns, environmental issues, and a lack of clarity about future tax laws and interest rates. Here’s an overview of
Contact Tampone at ktampone@cnybj.com
